In EC-CRT-001 trial involving ESCC patients treated with toripalimab plus CRT, univariable analyses of 16 genes of interest were conducted and only MCL-1 level was significantly associated with shorter OS (p = 0.03) and PFS (p = 0.024) (23). This evidence concerns the gene MCL1 and esophageal squamous cell carcinoma.